// App-Quantinova.ai

4461 : Epigenetics in doxorubicin and docetaxel-resistant triple negative breast cancer

Researchers

Presenter

  • Terra Sztain

Principal Investigators

  • Helena Chang

Medical Centers

  • UCLA Breast Ctr., Los Angeles, CA.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Ataxia telangiectasia

  • Breast cancer

  • Solid malignancies

  • Seizures sensorineural deafness ataxia mental retardation electrolyte imbalance

Biomarkers

  • B-cell lymphoma 2

  • N-Myc downregulated gene 1

  • N-Myc downregulated gene 2

  • Cluster of Differentiation 24

  • Progesterone receptor

  • Human epidermal growth factor receptor 2

  • Transforming Growth Factor Beta 1

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Doxorubicin

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved